Sort
15,273 grants matching “antimicrobial resistance”
A Novel Folate Antagonistic Strategy to Treat Drug Resistant Pseudomonas aeruginosa and Enterobacteriaceae
$217,938Liem Duy Nguyen · Case Western Reserve University · R21 · FY2016 · AI
Contribution of macrophages to Neisseria gonorrhoeae pathogenesis
$217,913Ana-Maria Dragoi · Louisiana State Univ Hsc Shreveport · P20 · FY2023 · GM
Optimized methods for isolation and characterization of bacteriophage by VT-FACS
$217,898Ian Fleming · Guild Associates, Inc. · R21 · FY2021 · AI
Computational Modeling and Design of Antimicrobial Peptides
$217,821Yiannis Kaznessis · University Of Minnesota · R01 · FY2008 · GM
Computational Modeling and Design of Antimicrobial Peptides
$217,767Yiannis Kaznessis · University Of Minnesota · R01 · FY2009 · GM
Membrane-Acting Lytic Peptides
$217,650Jun F Liang · The Trustees Of The Stevens Institute Of Technology · R15 · FY2007 · GM
Polymer Grafted Implant Surfaces with Biofilm Sensitizing Ability
$217,650Jun F Liang · The Trustees Of The Stevens Institute Of Technology · R15 · FY2007 · AI
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.
$217,605Patricia Ann Schachern · Earnano, Llc · R41 · FY2019 · HD
Training in Interdisciplinary Research to Reduce Antimicrobial Resistance (TIRAR)
$217,541Elaine Lucille Larson · Columbia University Health Sciences · T90 · FY2009 · NR
VALIDATION OF A HIGH THROUGHPUT SCREEN FOR KPC PLASMID EVICTION
$217,500James E Kirby · Beth Israel Deaconess Medical Center · R21 · FY2015 · AI
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
$217,500Bao Gia Vu · University Of Oklahoma Hlth Sciences Ctr · R21 · FY2024 · AI
Single Antigen Strategy for Prevention of Recurrent and Chronic Suppurative Otitis
$217,500Stephen I. Pelton · Boston Medical Center · R21 · FY2016 · DC
Chemical tools to investigate chain-flipping in quorum signal synthases
$217,496Rajesh Nagarajan · Boise State University · R21 · FY2023 · AI
Vaccine Treatment and Evaluation Unit: Phase IV Tuberculosis Therapeutics Trial
$217,479Karen Kotloff · University Of Maryland Baltimore · N01 · FY2017 · AI
Identification of Immunologic Mechanisms of Enhanced Ng Clearance Induced by Nm OMV-based Vaccines
$217,468Joseph A Duncan · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2022 · AI
Mechanisms of Enteric Burkholderia psuedomallei infection
$217,462Steven W. Dow · Colorado State University · R21 · FY2012 · AI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB
$217,406Gyanu Lamichhane · Johns Hopkins University · R21 · FY2015 · AI
Extracellular Matrix-Derived Nanoparticles for Repairing Lung Injury
$217,379Rebecca Long Heise · Virginia Commonwealth University · R21 · FY2020 · HL
DNA gyrase and quinolone resistance in tuberculosis
$217,323Public Health Research Institute · R01 · FY2003 · AI
Lactobacilli as a source of natural microbicides against HIV-1
$217,314Ruth Ingrid Connor · Dartmouth College · R21 · FY2007 · AI
A novel, two-armed autotherapy for mucosal infectious diseases
$217,307Mark C Herzberg · University Of Minnesota · R21 · FY2020 · DE
Type IV Secretion System Therapeutics
$217,135James E Kirby · Beth Israel Deaconess Medical Center · R21 · FY2010 · AI
The cystic fibrosis sputum compromises the ability of neutrophils to kill Staphylococcus aureus
$217,125Balazs Rada · University Of Georgia · R21 · FY2025 · AI
Evaluating Novel Multi-kinase Peptide Inhibitors as a Treatment for Rheumatoid Ar
$217,059David Men-Hwei Tsai · Ambryx Biotechnology, Inc. · R43 · FY2013 · AT
Antimicrobials from Mammalian Microbiomes
$217,000Robert Henry Cichewicz · University Of Oklahoma · R21 · FY2012 · AI